Q-omics provides the consensus-scored PDE4DIPP10 profile across patient tissues and cancer cell-line models. PDE4DIPP10 expression is associated with patient survival in 19 of 34 cancer types, with the highest sampling consensus in TGCT. Among the 18 cancer types available for tumor–normal comparison, PDE4DIPP10 is differentially expressed in 2, with the highest sampling consensus in HNSC. Additionally, PDE4DIPP10 RNA expression shows 6,254 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight TGCT, HNSC, and STAD as cancer lineages where PDE4DIPP10 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PDE4DIPP10 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PDE4DIPP10 survival associations across molecular data types. PDE4DIPP10 RNA expression shows survival associations in the most cancer types (19). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PDE4DIPP10 RNA expression–survival associations across cancer types. High PDE4DIPP10 expression shows unfavorable associations in TGCT and THCA, but favorable associations in CESC, LUSC, ESCA and HNSC. The TGCT Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify TGCT as the clearest survival context for PDE4DIPP10 RNA expression.
This table summarizes PDE4DIPP10 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 2. The strongest signals are observed in LUSC for RNA.
This table ranks reproducible tumor–normal expression differences for PDE4DIPP10. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PDE4DIPP10 shows higher tumor expression in HNSC and LUSC. The HNSC box plot shows higher PDE4DIPP10 RNA expression in tumor versus normal tissue (log2 FC = +0.059, t-test p = .010).
This table shows molecular features associated with PDE4DIPP10 in patient tissues and cancer cell lines. In patient samples, PDE4DIPP10 shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set.
